The comparisons between patients who underwent interferon-based therapy (n = 620) and those who underwent DAA therapy (n = 355) showed that the former were more frequently male, younger, infected with genotypes 1 and 2 HCV and had higher levels of ALT, eGFR, uric acid and hemoglobin; lower levels of NLR and FIB-4 index; and lower rates of hepatic steatosis (Table 1). The gene discussed is GPT; the disease is fatty liver disease.